REVVITY, INC. RVTY
We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees. Our common stock is listed on the New York Stock Exchange under the symbol "RVTY" and we are a component of the S&P 500 Index.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B | $2.66B | $2.88B | $2.78B | $2.26B | $2.12B |
| Cost of revenue | — | — | — | — | — | — | — | $1.44B | $475.3M | $437.4M |
| Gross profit | — | — | — | $1.99B | $2.43B | $2.11B | $1.40B | $1.34B | $1.07B | $1.01B |
| R&D | $215.8M | $196.8M | $216.6M | $221.6M | $200.3M | $146.4M | $189.3M | $194.0M | $139.5M | $124.2M |
| SG&A | $991.9M | $994.1M | $1.02B | $1.03B | $975.2M | $716.5M | $815.3M | $811.9M | $626.0M | $590.5M |
| Operating income | $356.6M | $346.7M | $300.6M | $742.7M | $1.26B | $867.3M | $362.0M | $323.9M | $295.6M | $294.6M |
| Interest expense | $92.2M | $96.3M | $98.8M | $104.0M | — | $49.7M | $63.6M | $67.0M | $43.9M | $41.5M |
| Pre-tax income | $268.3M | $316.1M | $183.0M | $651.8M | $1.20B | $800.1M | $237.1M | $257.7M | $296.7M | $244.1M |
| Income tax | $28.4M | $33.1M | $3.5M | $139.2M | $314.1M | $169.5M | $9.4M | $20.2M | $139.8M | $28.4M |
| Net income | $241.2M | $270.4M | $693.1M | $569.2M | $943.2M | $727.9M | $227.6M | $237.9M | $292.6M | $234.3M |
| EPS, basic | 2.07 | 2.21 | 5.56 | 4.51 | 8.12 | 6.52 | 2.06 | 2.15 | 2.67 | 2.14 |
| EPS, diluted | 2.07 | 2.20 | 5.55 | 4.50 | 8.08 | 6.49 | 2.04 | 2.13 | 2.64 | 2.12 |
| Shares, diluted (wtd. avg.) | $116.6M | $122.8M | $124.8M | $126.4M | $116.7M | $112.1M | $111.5M | $111.5M | $110.9M | $110.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $919.9M | $1.16B | $913.2M | $470.7M | $619.3M | $402.6M | $191.9M | $166.3M | $202.4M | $376.6M |
| Short-term investments | — | $0 | $689.9M | $0 | — | — | — | — | — | — |
| Receivables | $744.7M | $632.4M | $632.8M | $612.8M | $707.9M | $1.16B | $725.2M | $632.7M | $552.3M | $425.6M |
| Inventory | $379.5M | $367.6M | $428.1M | $405.5M | $425.9M | $514.6M | $356.9M | $338.3M | $351.7M | $246.8M |
| Total current assets | $2.24B | $2.35B | $3.00B | $3.29B | $2.44B | $2.24B | $1.37B | $1.23B | $1.20B | $1.19B |
| Property, plant and equipment | $479.2M | $482.2M | $509.7M | $482.9M | $485.5M | $368.3M | $318.2M | $318.6M | $298.1M | $145.5M |
| Goodwill | $6.61B | $6.46B | $6.53B | $6.48B | $6.63B | $2.64B | $3.11B | $2.95B | $3.00B | $2.25B |
| Other intangibles | $2.35B | $2.64B | $3.02B | $3.38B | $3.82B | $1.37B | $1.28B | $1.20B | $1.35B | $420.2M |
| Total assets | $12.17B | $12.39B | $13.56B | $14.13B | $15.00B | $7.96B | $6.54B | $5.98B | $6.09B | $4.28B |
| Accounts payable | $185.5M | $167.5M | $204.1M | $272.8M | $324.8M | $327.3M | $235.9M | $220.9M | $222.1M | $168.0M |
| Short-term debt | $588.8M | $242.0K | $721.9M | $470.9M | — | $380.9M | — | — | — | — |
| Total current liabilities | $1.33B | $653.1M | $1.45B | $1.54B | $1.21B | $1.65B | $762.8M | $771.6M | $950.9M | $603.4M |
| Long-term debt | $2.63B | $3.15B | $3.18B | $3.92B | $4.98B | $1.61B | $2.06B | $1.88B | $1.79B | $1.05B |
| Total liabilities | $4.92B | $4.73B | $5.69B | $6.75B | $7.86B | $4.22B | $3.72B | $3.39B | $3.59B | $2.12B |
| Retained earnings | $6.05B | $5.85B | $5.61B | $4.95B | $4.42B | $3.51B | $2.81B | $2.60B | $2.38B | $2.12B |
| Total equity | $7.25B | $7.67B | $7.87B | $7.38B | $7.14B | $3.74B | $2.81B | $2.58B | $2.50B | $2.15B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $582.9M | $628.3M | $91.3M | $679.8M | $1.41B | $892.2M | $363.5M | $311.0M | $288.5M | $350.6M |
| Depreciation and amortisation | $405.3M | $427.8M | $431.8M | $427.0M | $311.4M | $201.6M | $214.0M | $180.6M | $105.0M | $100.0M |
| Stock-based compensation | $22.8M | $37.8M | $41.4M | $51.5M | $29.7M | $26.9M | $31.5M | $28.8M | $25.4M | $17.2M |
| Capital expenditure | $73.5M | $86.6M | $81.4M | $85.6M | $86.0M | $63.6M | $76.3M | $93.3M | $39.1M | $31.7M |
| Investing cash flow | -$17.4M | $776.2M | $1.31B | -$132.9M | -$4.11B | -$504.5M | -$487.6M | -$159.9M | -$1.27B | -$83.9M |
| Financing cash flow | -$857.5M | -$1.13B | -$947.1M | -$661.8M | $2.94B | -$202.9M | -$150.1M | -$179.2M | $782.2M | -$115.0M |
| Dividends paid | $32.8M | $34.5M | $35.0M | $35.3M | $32.4M | $31.2M | $31.1M | $31.0M | $30.8M | $30.8M |
| Buybacks | $820.8M | $369.6M | $388.9M | $80.6M | $73.1M | $6.9M | $6.3M | $57.4M | $3.8M | $151.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000031791-26-000012.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |
| TXG | 10x Genomics, Inc. | $8.14B | — | 5.2% |